News
Hong Kong’s VMS Group eyes up to $400m for flagship PE fund
Hong Kong alternative asset management firm VMS Group is targeting $300 million for its flagship private equity fund, with a hard cap of $400 million.
Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is in advanced discussion with its Company's Chairman and Chief Executive Officer, Mr. Hong Zhida, to acquire Mr Hong's partial stake in Shanghai Bao Pharmaceutical Company Limited.
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca
SHANGHAI, June 16, 2023 /PRNewswire/ -- Cholesgen (Shanghai) Co.Ltd. ('Cholesgen') today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca.
Siemens to spend $2.2 bln to ramp up global production
SINGAPORE/ZURICH, June 15 (Reuters) - Siemens (SIEGn.DE) will spend 2 billion euros ($2.2 billion) on a new global investment plan, the German engineering group said on Thursday, to make its operations more resilient against supply chain disruptions and geopolitical tensions.
Metagen Therapeutics Completes Series A Financing Raising a Total of $12.1 Million
TSURUOKA, Japan, June 15, 2023 /PRNewswire/ -- Metagen Therapeutics (President & CEO: Taku Nakahara), a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen.
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
TOKYO and SAN DIEGO, June 14, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Cullgen Inc. (President and CEO: Ying Luo, Ph.D., "Cullgen") today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
SHANGHAI and HANGZHOU, China, June 14, 2023 /PRNewswire/ -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced today that the first healthy volunteer dosed in the Phase 1 study of their oral small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), MDR-001 for the treatment of obesity and type 2 diabetes mellitus (T2DM).
Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays
SEOUL, South Korea, June 14, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson’s Disease
ROCKVILLE, Md. and SEOUL, South Korea, June 12, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) and Daewoong Pharmaceutical (KRX: 069620.KS) today announced the expansion of their open collaboration strategy by investing in Vincere Biosciences, a Cambridge, MA-based company developing therapeutics targeting mitophagy.
